Albumin Biomaterials for Use in Implants and Related Devices (08-067)

Market Overview:

With ever-advancing implantation technologies, there arises a growing need for materials that are biocompatible and able to reduce the risk of biomaterial-centered infections (BCI). Such infections are a key limitation in the performance of various implants, and play a crucial role in the treatment of the ear condition known as otitis media with pressure equalization tubes. Myringotomy, the procedure used to treat otitis media, has an estimated BCI incidence rate of approximately 4.3% annually. The concern for biofilm formation on implanted devices also makes new materials that can mitigate these risks highly desirable. Clemson University researchers have developed a material, based on the serum albumins, that can be used as a component of a device body or as a coating for current devices. These materials have shown a reduction in bacterial adhesion in vivo, increasing antibacterial properties. Additionally, these coatings have been verified to not compromise the bone integration with implants. 

Application                                                               Stage of Development

Orthopedic Devices/Medical Implants                     In vivo proof of concept demonstrated in  animal model

Advantages

• Provides enhanced bacterial and biofilm resistance, allowing for a reduction in risk of infection. 

• Delivers therapeutic agents to the site of implant, providing long-term protection

• Material does not compromise an implant’s bone integration, making it ideal for coatings

Technical Summary

The albumin-based material developed by Clemson researchers allows for device bodies or protein-based coatings for devices to be fabricated. These devices are able to gain improved properties through the characteristics associated with the albumin protein family, specifically the serum albumins. Albumin’s resistance towards bacterial adhesion provides these devices with improved antibacterial and anti-biofilm qualities. These albumin proteins also have the ability to bind physiologically vital agents such as cations, fatty acids, and hormones, and are capable of binding various pharmaceuticals. Therefore, this technology can be used in procedures that require the delivery of one or more therapeutic agents that will benefit the patient. Ideally, these albumin materials will allow reduction of material-based infections in various procedures, including those such as a myringotomy or the introduction of bone implants or artificial heart valves.

View printable PDF version of this technology

____________________________________________________________________________________________

Inventor:                        Dr.  Igor Luzinov, Benjamin R. Whatley, Xuejun Wen, & Suraj Sharma

Patent Type:                  Utility

Serial Number:              13/905,726

CURF Ref No:              08-067

Patent Information:
Category(s):
Biomedical Sciences
For Information, Contact:
Andy Bluvas
Technology Commercialization Officer
Clemson University Research Foundation
bluvasa@clemson.edu
Inventors:
Igor Luzinov
Xuejun Wen
Suraj Sharma
Ben Whatley
Keywords:
Biomaterials - Other
Drugs/Pharma - Drug Delivery
Medical Device
Molecular Therapies
© 2018. All Rights Reserved. Powered by Inteum